Spotty insurance coverage for GLP-1 drugs gets worse

NPR | By Sydney Lupkin

Published April 15, 2026 at 5:39 PM EDT

Insurance coverage of blockbuster obesity drugs has been spotty at best over the years, and it looks like things are getting worse, not better. Plans are dropping coverage or restricting it further.

Sydney Lupkin

Sydney Lupkin is the pharmaceuticals correspondent for NPR.

See stories by Sydney Lupkin

WRVO is at a critical moment.

Recent cuts to federal funding are challenging our mission to serve central and upstate New York with trusted journalism, vital local coverage, and the diverse programming that informs and connects our communities. This is the moment to join our community of supporters and help keep journalists on the ground, asking hard questions that matter to our region.

Stand with public media and make your gift today—not just for yourself, but for all who depend on WRVO as a trusted resource and civic cornerstone in central and upstate New York.

Support WRVO now